Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

VivaCell Biotechnology

VivaCell Biotechnology?uq=w9if130k
2003 FOUNDED
M&A STATUS
1-10 EMPLOYEES
M&A LATEST DEAL TYPE
2 FINANCING ROUNDS
Description

Developer of pharmaceutical drugs created to focus on new non-psychotropic cannabinoids for the treatment of inflammatory and neurodegenerative diseases. The company's operations include development of cannabidiol and cannabigerol chemical derivatives that improve the therapeutic properties of the natural hit compounds which addresses unmet clinical need in the treatment of multiple sclerosis, Huntington's disease and scleroderma.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Parent Company
Emerald Health Research
Primary Office
  • Parque Científico Tecnológico de Córdoba (Rabanales 21)
  • Calle Astrónoma Cecilia Payne, Edificio Centauro, Planta 1
  • 14014 Córdoba
  • Spain

+34 957 00 00 00

VivaCell Biotechnology Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore VivaCell Biotechnology‘s full profile, request access.

Request full access to PitchBook

VivaCell Biotechnology Executive Team (3)

Name Title Board
Seat
Contact
Info
María del Pilar Díaz Espejo-Saavedra Chief Financial Officer
Mari Luz Bellido Ph.D Managing Director
Eduardo Muñoz Ph.D Founder